Clinical Trials
2 trialsNCT02386826 2023-09-21
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
SCRI Development Innovations, LLC
Phase 1 Completed
NCT02019693 2023-03-21
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed